138 related articles for article (PubMed ID: 27379204)
1. Rationally Repurposing Ruxolitinib (Jakafi (®)) as a Solid Tumor Therapeutic.
Tavallai M; Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2016; 6():142. PubMed ID: 27379204
[TBL] [Abstract][Full Text] [Related]
2. Ruxolitinib synergizes with DMF to kill via BIM+BAD-induced mitochondrial dysfunction and via reduced SOD2/TRX expression and ROS.
Tavallai M; Booth L; Roberts JL; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(14):17290-300. PubMed ID: 26981780
[TBL] [Abstract][Full Text] [Related]
3. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
[TBL] [Abstract][Full Text] [Related]
4. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells.
Booth L; Roberts JL; Samuel P; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
Cancer Biol Ther; 2018 Jun; 19(6):525-533. PubMed ID: 29405820
[TBL] [Abstract][Full Text] [Related]
5. Neratinib and entinostat combine to rapidly reduce the expression of K-RAS, N-RAS, Gα
Booth L; Roberts JL; Sander C; Lalani AS; Kirkwood JM; Hancock JF; Poklepovic A; Dent P
Cancer Biol Ther; 2019; 20(5):700-710. PubMed ID: 30571927
[TBL] [Abstract][Full Text] [Related]
6. The afatinib resistance of in vivo generated H1975 lung cancer cell clones is mediated by SRC/ERBB3/c-KIT/c-MET compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Webb T; Leon D; Chen J; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(15):19620-30. PubMed ID: 26934000
[TBL] [Abstract][Full Text] [Related]
7. PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide.
Booth L; Roberts JL; Poklepovic A; Gordon S; Dent P
Oncotarget; 2017 Jan; 8(1):1449-1468. PubMed ID: 27903966
[TBL] [Abstract][Full Text] [Related]
8. GZ17-6.02 and axitinib interact to kill renal carcinoma cells.
Booth L; West C; Moore RP; Hoff DV; Dent P
Oncotarget; 2022; 13():281-290. PubMed ID: 35136485
[TBL] [Abstract][Full Text] [Related]
9. [Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
Booth L; Roberts JL; Tavallai M; Chuckalovcak J; Stringer DK; Koromilas AE; Boone DL; McGuire WP; Poklepovic A; Dent P
Oncotarget; 2016 Apr; 7(17):23608-32. PubMed ID: 27015562
[TBL] [Abstract][Full Text] [Related]
10. The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo.
Booth L; Roberts JL; Sander C; Lee J; Kirkwood JM; Poklepovic A; Dent P
Oncotarget; 2017 Mar; 8(10):16367-16386. PubMed ID: 28146421
[TBL] [Abstract][Full Text] [Related]
11. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract][Full Text] [Related]
12. GZ17-6.02 and Pemetrexed Interact to Kill Osimertinib-Resistant NSCLC Cells That Express Mutant ERBB1 Proteins.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Front Oncol; 2021; 11():711043. PubMed ID: 34490108
[TBL] [Abstract][Full Text] [Related]
13. Multi-kinase inhibitors interact with sildenafil and ERBB1/2/4 inhibitors to kill tumor cells in vitro and in vivo.
Booth L; Albers T; Roberts JL; Tavallai M; Poklepovic A; Lebedyeva IO; Dent P
Oncotarget; 2016 Jun; 7(26):40398-40417. PubMed ID: 27259258
[TBL] [Abstract][Full Text] [Related]
14. The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib.
Booth L; Roberts JL; Poklepovic A; Dent P
Front Oncol; 2019; 9():650. PubMed ID: 31380285
[TBL] [Abstract][Full Text] [Related]
15. The multi-kinase inhibitor lenvatinib interacts with the HDAC inhibitor entinostat to kill liver cancer cells.
Roberts JL; Poklepovic A; Booth L; Dent P
Cell Signal; 2020 Jun; 70():109573. PubMed ID: 32087304
[TBL] [Abstract][Full Text] [Related]
16. GZ17-6.02 and palbociclib interact to kill ER+ breast cancer cells.
Booth L; West C; Moore RP; Von Hoff D; Dent P
Oncotarget; 2022; 13():92-104. PubMed ID: 35035775
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2.
Ishida S; Akiyama H; Umezawa Y; Okada K; Nogami A; Oshikawa G; Nagao T; Miura O
Oncotarget; 2018 Jun; 9(42):26834-26851. PubMed ID: 29928488
[TBL] [Abstract][Full Text] [Related]
18. Valproate augments Niraparib killing of tumor cells.
Booth L; Roberts JL; Rais R; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):797-808. PubMed ID: 29923797
[TBL] [Abstract][Full Text] [Related]
19. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells.
Booth L; Roberts JL; West C; Dent P
Oncotarget; 2024 Mar; 15():159-174. PubMed ID: 38441437
[TBL] [Abstract][Full Text] [Related]
20. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells.
Yacoub A; Park MA; Hanna D; Hong Y; Mitchell C; Pandya AP; Harada H; Powis G; Chen CS; Koumenis C; Grant S; Dent P
Mol Pharmacol; 2006 Aug; 70(2):589-603. PubMed ID: 16622074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
